Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation is the most common arrhythmia in clinic. It can lead to heart failure or
stroke, and has a high disability rate and mortality rate. At present, although
radiofrequency ablation can cure atrial fibrillation, the success rate is only 50~70%, and
has a high recurrence rate. In recent decades, no effective new antiarrhythmic drugs have
been introduced, but there are side effects in long-term application of the existing
antiarrhythmic drugs. Therefore, it is urgent to provide new and effective antiarrhythmic
drugs.
Autophagy level of atrial myocytes in atrial fibrillation patients was significantly higher
than that in sinus rhythm. Hydrochloroquine (HCQ) is a hydroxychloroquine sulfate composed of
4- amino quinoline compounds. As an effective inhibitor for autophagy, HCQ could effectively
prevent the increased autophagy level of atrial myocytes in atrial fibrillation rabbits,
prevent atrial effective refractory period (AERP) shortening, and decrease the rate and
duration of atrial fibrillation.
At present, hydroxychloroquine is mainly used in the treatment of rheumatic immune system
diseases and anti malaria. Because of its good safety and small side effects, HCQ has become
an indispensable member of drugs in the combined treatment of rheumatoid arthritis and
systemic lupus erythematosus patients. In recent years, studies have reported that
hydroxychloroquine plays an important role in the prevention and treatment of cardiovascular
diseases. Chloroquine could effectively shorten the action potential of atrial myocytes by
blocking the inward rectifier potassium ion channel (Kir2.1) and reducing the inward
potassium ion current Ik1. HCQ could also reduce 72% (P=0.002), and 70% for the risk of
coronary heart disease, stroke, and transient ischemic disease. So the investigators
speculate that HCQ may be a potential drug to block the occurrence of acute atrial
fibrillation.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University